close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics, Inc. - Common Stock (NQ:VVOS)

1.520 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vivos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Launch of DNA Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Collaboration, Expansion into MENA Region
Via Investor Brand Network
News headline image
Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams
Vivos Therapeutics Announces Strategic Agreements with Ormco and On Demand Orthodontist Vivos Therapeutics, Inc. (NASDAQ: VVOS), a prominent medical device 
Via Spotlight Growth
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters New Strategic Agreements with Ormco and On Demand Orthodontist
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces NYT Best-Selling Author James Nestor as Keynote Speaker for Upcoming Breathing Wellness Conference
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, YTD 2023 Financial, Operational Report
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Date for Rescheduled Q2 2023 Financial Results Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Reschedule Q2 2023 Financial Results Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans to Release Q2 2023 Financial Numbers, Schedules Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2023 Financial Numbers, Corporate Update
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q1 2023 Financial Numbers, Host Earnings Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Proactive Studio Podcast
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces New Strategic Initiatives
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on ‘Game-Changing’ Appliance Treatment for Migraines
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY Financial and Operational Report
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2022 Results, Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at 35th Annual ROTH Conference
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Expands Product Portfolio, Revenue Potential Through Strategic Acquisition
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Emerging Growth Conference
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of $8M Private Placement
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters into Private Placement Agreement
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA Clearance of Proprietary Oral Appliance for Obstructive Sleep Apnea Treatment
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, Q3 Financial Report, Operational Update
Via Investor Brand Network
Topics Regulatory Compliance
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on Q2 Q3 2022 Financial Results, Announces Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Creates Strategic Medical Billing Partnership, New Revenue Stream
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives NASDAQ Notification Regarding Q3 Quarterly Report Filing
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Update on Revenue Recognition Review
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 Earnings Delay
Via Investor Brand Network
Vivos Announces 4th Annual Breathing Wellness Conference in Cancún, Mexico, With Full Slate of World-Renowned Speakers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos") is excited to announce the fourth annual Breathing Wellness Conference, which will take place Oct. 26-29, 2022, at the Hilton Hotel in Cancún, Mexico.... 
Via Newswire.com
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today